Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More

Alector Inc (ALEC)

Alector Inc (ALEC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL001 in Amyotrophic Lateral Sclerosis (ALS)

Randomized, placebo-controlled Phase 2 trial will enroll patients with C9orf72-associated ALS

ALEC : 26.51 (+4.12%)
Alector Provides Executive Leadership Update

Planned Transitions Announced for Shehnaaz Suliman, M.D., MBA, MPhil, President and Chief Operating Officer and Robert Paul, M.D., Ph.D., Chief Medical Officer

ALEC : 26.51 (+4.12%)
Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of 0.00% and -26.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ALEC : 26.51 (+4.12%)
Alector: Q2 Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ Alector Inc. (ALEC) on Tuesday reported a loss of $55.1 million in its second quarter.

ALEC : 26.51 (+4.12%)
Alector Reports Second Quarter 2021 Financial Results

Presented twelve-month data from ongoing AL001 open-label Phase 2 study in FTD-GRN at the 2021 Alzheimer's Association International Conference (AAIC)

ALEC : 26.51 (+4.12%)
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALEC : 26.51 (+4.12%)
Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation

AL001 Successfully Restored Progranulin to Normal Levels in FTD-GRN Patients

ALEC : 26.51 (+4.12%)
Alector to Present New Data from Frontotemporal Dementia and Alzheimer's Disease Programs at the 2021 Alzheimer's Association International Conference

Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRN

ALEC : 26.51 (+4.12%)
Alector's (ALEC) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Alector, Inc. (ALEC).

ALEC : 26.51 (+4.12%)
Pharma Stock Roundup: GSK's New Deal With Alector, MRK & AZN's FDA Updates

Glaxo (GSK) to co-develop Alector's two candidates for neurodegenerative diseases. FDA updates for Merck (MRK) and AstraZeneca (AZN)

AZN : 55.78 (-1.45%)
GSK : 38.90 (-0.54%)
MRK : 71.32 (-0.90%)
LLY : 229.87 (-0.51%)
AMGN : 218.66 (+0.60%)
ALEC : 26.51 (+4.12%)

Barchart Exclusives

US Stock Markets: Stop the Seasonal Madness
A popular theme on financial television these days is September is a seasonally bearish time for US stock markets. The evidence does not support this idea. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar